Grifols, S.A. (NASDAQ:GRFS) Receives $10.30 Consensus Price Target from Brokerages

Grifols, S.A. (NASDAQ:GRFS) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $10.30.

Several equities analysts recently commented on GRFS shares. Wall Street Zen upgraded shares of Grifols from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 7th. JPMorgan Chase & Co. upped their price target on shares of Grifols from $7.60 to $10.30 and gave the company a “neutral” rating in a research note on Tuesday, June 17th. Zacks Research upgraded shares of Grifols to a “hold” rating in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Grifols in a research note on Tuesday, August 5th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a research report on Saturday, September 27th.

Institutional Investors Weigh In On Grifols

Several institutional investors and hedge funds have recently bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Grifols by 2.4% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,192 shares of the biotechnology company’s stock worth $427,000 after purchasing an additional 1,114 shares during the period. Oppenheimer Asset Management Inc. lifted its position in Grifols by 4.9% during the second quarter. Oppenheimer Asset Management Inc. now owns 62,991 shares of the biotechnology company’s stock worth $569,000 after purchasing an additional 2,928 shares during the period. Sequoia Financial Advisors LLC lifted its position in Grifols by 14.9% during the first quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 3,399 shares during the period. Versant Capital Management Inc bought a new stake in Grifols during the first quarter worth about $28,000. Finally, Cerity Partners LLC lifted its position in Grifols by 22.8% during the first quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 4,129 shares during the period.

Grifols Trading Down 3.4%

GRFS stock opened at $9.61 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.95 and a current ratio of 2.64. The company’s 50-day simple moving average is $10.12 and its 200 day simple moving average is $8.84. Grifols has a 52 week low of $6.19 and a 52 week high of $11.14. The company has a market capitalization of $6.61 billion, a PE ratio of 8.21, a price-to-earnings-growth ratio of 0.34 and a beta of 0.69.

Grifols Announces Dividend

The company also recently disclosed a special dividend, which was paid on Wednesday, August 20th. Investors of record on Tuesday, August 12th were given a dividend of $0.1404 per share. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols’s dividend payout ratio is currently 11.97%.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.